Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
Here's How Biotechs Plan To Attack Cancer, Other Diseases In 2019
on November 21, 2018 at 7:05 am
CAR-T is a form of immunotherapy that involves removing immune cells from ... Novartis was the first to gain approval for a CAR-T treatment in a blood cancer. Gilead later acquired Kite Pharma before ... […]
Immunotherapy drug to be made available for some NHS patients with advanced skin cancer
on November 21, 2018 at 2:01 am
An immunotherapy drug will be made available to some patients with advanced melanoma skin cancer on the NHS in England. Pembrolizumab (Keytruda) will soon be an option for patients whose melanoma has ... […]
Immunotherapy Combos Expand Across Lung Cancer Subtypes
on November 20, 2018 at 11:58 am
Combinations with checkpoint inhibitors and chemotherapy have become a standard therapeutic choice for some patients with non–small cell lung cancer (NSCLC), and such regimens continue to be explored ... […]
BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
on November 20, 2018 at 3:00 am
TEL AVIV, Israel, Nov. 20, 2018 /PRNewswire/ -- BioLineRx Ltd. BLRX, -4.48% (tase:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that the U.S. Fo... […]
Genentech to Co-Develop Immunocore Cancer Immunotherapy Candidate IMC-C103C
on November 19, 2018 at 7:36 pm
Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, illustrated in a company video, is designed to apply the power of T-cell receptors (TCRs) to recognize int... […]
People Who Are Obese Respond Better to Some Cancer Immunotherapy Drugs
on November 16, 2018 at 12:45 pm
In a surprising and counterintuitive finding, researchers say they have evidence that cancer patients who are obese respond better than normal-weight cancer patients to a category of immunotherapy dru... […]
AstraZeneca lung cancer immunotherapy trial fails, dealing blow to company
on November 16, 2018 at 12:06 pm
A cancer immunotherapy trial by AstraZeneca failed to show improved survival for patients, sending the company’s stock downward. The British drugmaker said Friday that data from the Phase III ... […]
Recent Breakout Stock Sacrifices Buy Zone On Lung-Cancer Failure
on November 16, 2018 at 8:48 am
AstraZeneca (AZN) sacrificed a buy zone Friday after its immunotherapy regimen failed to improve overall survival in lung cancer patients. On the stock market today, AstraZeneca stock slipped 1.8%, to ... […]
PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors
on November 15, 2018 at 6:00 am
OXFORD, England and SAN FRANCISCO, Nov. 15, 2018 /PRNewswire/ -- PsiOxus Therapeutics, Ltd. (PsiOxus) and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced a research pr... […]
Immunotherapy Is 'Here to Stay' in Kidney Cancer
on November 14, 2018 at 7:38 am
Patients with renal cell carcinoma have more treatment options than ever before, though many questions still remain unanswered, according to Toni Choueiri, M.D. “The field is continuing to evolve, and ... […]
via Google News and Bing News